Alvaiz
(Eltrombopag)Teva Pharmaceuticals, Inc.
Usage: ALVAIZ (eltrombopag) is indicated for treating thrombocytopenia in patients with persistent or chronic immune thrombocytopenia, chronic hepatitis C, and severe aplastic anemia who have not responded adequately to other therapies. It is not approved for myelodysplastic syndromes or with direct-acting antiviral agents for hepatitis C.